- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01424839
Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors (SIOPCNSGCTII)
SIOP CNS GCT II: Prospective Trial for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Intracranial Germ Cell Tumors
STUDY DESIGN:
Prospective, non-randomised multicentre study with patients stratified according to risk groups INVESTIGATIONAL MEDICINAL PRODUCTS The IMPs on this trial are Carboplatin, Cisplatin, Ifosfamide and Etoposide (as approved by German competent authority).
PRIMARY OBJECTIVES:
Germinoma
- To maintain current high event-free survival (EFS) rates using a risk adapted approach
- In localised germinoma: to omit whole brain and spinal irradiation by using combined treatment with standard chemotherapy and ventricular irradiation (+/- boosts)
- In bifocal tumours (pineal + suprasellar): to treat as non-metastatic disease and to omit whole brain and spinal irradiation by using combined treatment with standard chemotherapy and ventricular irradiation (+/- boosts)
- In metastatic disease: to maintain current excellent EFS in metastatic germinoma with craniospinal irradiation Malignant non-germinoma
To improve EFS:
- by dose escalation of chemotherapy in patients identified as high risk at diagnosis ( age < 6 years and/or AFP serum / CSF > 1000 ng/ml)
- by standardising the surgical approach for residual disease after treatment Teratoma
- To register patients and collect data regarding diagnostics, treatment and outcome in order to develop future treatment strategies
SECONDARY OBJECTIVES:
Germinoma
- To minimise long term effects of irradiation by sparing spinal and whole brain radiotherapy in non-metastatic disease Malignant non-germinoma
- In standard risk to maintain EFS with chemotherapy and local irradiation Teratoma
- To evaluate the influence of surgery and treatment on outcome to assist in the development of a fu-ture treatment strategy For all histological subtypes
- To improve accuracy of diagnosis and staging in all registered patients
- To standardise neurosurgical intervention
- For all patients requiring biopsy or resection according to protocol guidelines, to collect and to store tumour material, and CSF where possible, for use in future biological studies.
ENDPOINTS / Criteria for evaluation:
Main end point
Event-free survival, defined as minimum time from the date of diagnosis to:
- Death from any cause
- Relapse
- Progressive disease on therapy
- Or second malignancy
Secondary end points
- Overall survival, defined as time to death from any cause, measured from the date of diagnosis
- Short and long term toxicity.
Study Overview
Status
Conditions
Detailed Description
PATIENT POPULATION Age of patients: no lower or upper age limit; Estimated number: 400 malignant germ cell tumours
Diagnosis and main criteria for inclusion/exclusion:
Intracranial Germ Cell tumours of any histology and intracranial site and dissemination
Inclusion criteria
- Main residence in one of the participating countries
- Primary diagnosis of an intracranial germ cell tumour
- Written consent for trial participation, treatment according to the protocol and consent for data trans-fer
Exclusion criteria:
- Tumour entity other than primary intracranial germ cell tumour or CNS GCT as second malignancy
- Primary diagnosis pre-dating the opening of SIOP CNS GCT II in the participating country of registration
- Medical, psychiatric or social conditions incompatible with trial treatment or treatment according to protocol is not intended
- Participation within a different trial for treatment of germ cell tumours and/or concurrent treatment within any other clinical trial. The only exceptions to this are trials with different endpoints, involving aspects of supportive treatment which can run parallel to SIOP CNS GCT II without influencing the outcome of this trial e.g. trials on antiemetics, antimycotics, antibiotics, strategies for psychosocial support etc.
- Pregnancy and lactation
- Any treatment not given according to protocol prior to registration
TREATMENT:
GERMINOMA
Chemotherapy:
- Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide Note: Bifocal germinoma (pineal+suprasellar) are treated as non-metastatic germinoma, if stag-ing shows no additional dissemination
- Metastatic or incompletely staged germinomas (± teratoma) Do not receive chemotherapy in this protocol
Radiotherapy:
- Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)
- Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles
- Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracranial metastases and spinal deposits (total tumour dose 40 Gy)
- Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)
- Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)
NON-GERMINOMA (± TERATOMA)
Chemotherapy:
- Standard risk non-germinomatous malignant GCT Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment )
- High risk non-germinomatous malignant GCT Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support
Resection of residual tumour after 3 courses chemotherapy (if indicated), followed by: 4th course. If vi-able cells are found in the resected tumour specimen patient is transferred to the high risk arm
Radiotherapy for standard and high risk non-germinomatous malignant GCT:
- Patients with localised disease at diagnosis After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
- Patients with metastatic disease at diagnosis After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
SPECIAL ASPECTS:
Central response evaluation on a national basis:
Germinoma: In all patients with localised germinoma a central national radiological review is mandatory for response evaluation to chemotherapy and decision if only ventricular irradiation or an additional tu-mour boost has to be performed.
Non-Germinoma: After three courses of chemotherapy to evaluate response to treatment and to deter-mine necessity of surgery in case of residual before radiotherapy.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Gabriele Calaminus, MD
- Phone Number: +492518358060
- Email: gabriele.calaminus@ukmuenster.de
Study Contact Backup
- Name: Carmen Teske
- Phone Number: +492518358055
- Email: carmen.teske@ukmuenster.de
Study Locations
-
-
-
Muenster, Germany, 48129
- Recruiting
- University Hospital Muenster
-
Contact:
- Gabriele Calaminus, MD
- Phone Number: +492518358060
- Email: gabriele.calaminus@ukmuenster.de
-
Contact:
- Carmen Teske
- Phone Number: +492518358055
- Email: carmen.teske@ukmuenster.de
-
Principal Investigator:
- Gabriele Calaminus, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Main residence in one of the participating countries
- Primary diagnosis of an intracranial germ cell tumour
- Written consent for trial participation, treatment according to the protocol and consent for data transfer
Exclusion Criteria:
- Tumour entity other than primary intracranial germ cell tumour or CNS GCT as second malignancy
- Primary diagnosis pre-dating the opening of SIOP CNS GCT II in the participating country of registration
- Medical, psychiatric or social conditions incompatible with trial treatment or treatment according to protocol is not intended
- Participation within a different trial for treatment of germ cell tumours and/or concurrent treatment within any other clinical trial. The only exceptions to this are trials with different endpoints, involving aspects of supportive treatment which can run parallel to SIOP CNS GCT II without influencing the outcome of this trial e.g. trials on antiemetics, antimycotics, antibiotics, strategies for psychosocial support etc.
- Pregnancy and lactation
- Any treatment not given according to protocol prior to registration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Germinoma metastatic
• Metastatic or incompletely staged germinomas (± teratoma) Do not receive chemotherapy in this protocol Radiotherapy
|
|
Other: germinoma non-metastatic
Chemotherapy: • Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide Note: Bifocal germinoma (pineal+suprasellar) are treated as non-metastatic germinoma, if staging shows no additional dissemination Radiotherapy
|
• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide
|
Other: Non-germinoma non-metastatic standard risk
Chemotherapy: • Standard risk non-germinomatous malignant GCT Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions |
Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment )
• Patients with localised non-germinomatous disease at diagnosis After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
|
Other: Non-Germinoma metastatic standard risk
Chemotherapy Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
|
Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment )
|
Other: Non-germinoma non-metastatic high risk
Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
|
• Patients with localised non-germinomatous disease at diagnosis After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support
|
Other: Non-Germinoma metastatic high risk
Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
|
Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support
|
No Intervention: Teratoma
collection of information on surgery, applied treatment and outcome
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
survival
Time Frame: 5 years event free survival
|
Survival rates in respect to applied treatment , according to Kaplan-Meier estimation , 5 years event free survival
|
5 years event free survival
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
short and long term toxicity
Time Frame: until 7 years after start of trial
|
toxicity of treatment will be assessed with CTC criteria, severe toxicity will be analysed by safety desk
|
until 7 years after start of trial
|
overall survival
Time Frame: 7 years after start of trial
|
Overall survival will be measured by Kaplan -Meier Estimation , 5 years overall survival
|
7 years after start of trial
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gabriele Calaminus, MD, University Hospital Muenster
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Carboplatin
- Etoposide
- Etoposide phosphate
- Cisplatin
- Ifosfamide
- Isophosphamide mustard
Other Study ID Numbers
- UKM08_0057
- 2009-018072-33 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracranial Germ Cell Tumors
-
Chengcheng GuoRecruitingSurgery | Intracranial Germ Cell Tumor | Intracranial Germ Cell CNS Tumor, ChildhoodChina
-
Beijing Neurosurgical InstituteUnknownIntracranial Germ Cell TumorChina
-
Astellas Pharma Global Development, Inc.CompletedTumors | Incurable Platinum Refractory Germ Cell TumorsUnited States
-
Massachusetts General HospitalCompletedMelanoma | Glioblastoma | Intracranial TumorsUnited States
-
Mayo ClinicCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Children's Oncology GroupNot yet recruitingChildhood Central Nervous System Germinoma | Intracranial Germ Cell Tumor
-
Memorial Sloan Kettering Cancer CenterMayo Clinic; University of Chicago; University of Pittsburgh; University of Southern... and other collaboratorsActive, not recruiting
-
Hoosier Cancer Research NetworkMerck Sharp & Dohme LLCCompletedGerm Cell TumorsUnited States
-
Barbara Ann Karmanos Cancer InstituteWashington University School of MedicineRecruitingBreast Cancer | Rectal Cancer | Neuroendocrine Tumors | Metastatic Brain Tumor | Intracranial GliomaUnited States
Clinical Trials on craniospinal irradiation
-
Memorial Sloan Kettering Cancer CenterCompletedLeptomeningeal MetastasesUnited States
-
Tata Memorial CentreRecruitingMedulloblastoma, WNT-activatedIndia
-
St. Jude Children's Research HospitalActive, not recruitingEpendymomaUnited States, Canada
-
Memorial Sloan Kettering Cancer CenterFred Hutchinson Cancer CenterActive, not recruitingLeptomeningeal MetastasesUnited States
-
University Hospital HeidelbergRecruiting
-
Heidelberg UniversityRecruiting
-
University of MinnesotaCompletedProteomicsUnited States
-
University of MichiganTerminatedPsoriasis | Mycosis Fungoides | Atopic Dermatitis | Alopecia | Urticaria | Stretch Marks | DermatosesUnited States
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruiting
-
Regione Emilia-RomagnaCompleted